NanoSphere Health Sciences Expands to Indiana With Evolve Formulas NanoSerum™ Hemp
Evolve Formulas Introduces New Hemp-Derived Product to Indiana Market, Launching in Mid-September
DENVER, Sept. 11, 2018 /PRNewswire/ -- NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology leader behind the patented NanoSphere Delivery System™, has entered into a revenue-sharing agreement to expand its Evolve Formulas product line to Indiana with Jeff DeHart, Managing Member of Evolve Formulas of Indiana, LLC. Under the agreement, NanoSphere will introduce a new, hemp-derived offering to the Indiana market. The NanoSerum™ Hemp products will be available for purchase in mid-September.
NanoSerum™ Hemp, like the other Evolve Formulas products, will leverage NanoSphere Health Sciences' next-generation NanoSphere Delivery System™ to provide fast-acting relief from pain and inflammation. Similar to marijuana, hemp is derived from the cannabis plant and carries a vast range of medical benefits; however, it is genetically distinct and does not contain THC. The hemp-derived NanoSerum™ will be available in 5ML and 10ML sizes. There are already 1,500 pre-orders to-date.
"With a proven track record of success already under our belt in Colorado—we are eager to continue Evolve Formulas' expansion by forging a path into the Midwest with an exciting new product, which delivers the benefits of hemp precisely and effectively," said Robert Sutton, CEO and Chairman of NanoSphere Heath Sciences and Evolve Formulas. "Bringing our unique delivery system to the residents of Indiana will serve to not only educate the public on the extraordinary medical potential of hemp, but also set the bar for a high standard of hemp-derived products in this untapped market."
NanoSphere Health Sciences utilizes a method of nano-encapsulating cannabis molecules in lipid membranes so they can be transported through layers of the skin and into the bloodstream in minutes. This provides rapid results, precise dosages and high bioavailability of cannabis which is ideal for localized pain and inflammation, as well as providing systemic therapy and relief from anxiety. With plans to expand into pharmaceutical, nutraceutical, cosmeceutical and animal health divisions in the coming years, the new hemp serum is another example of how NanoSphere's technology can be applied to various formats and industries.
NanoSerum™ is currently commercially available in Colorado under the company's brand name Evolve Formulas and will soon launch in California, Arizona and Nevada. The company also just announced a partnership with Delta 9 Cannabis INC to bring Evolve Formulas products into the Canadian market. In mid-September, the NanoSerum™ Hemp products will be available throughout Indiana with plans to expand into additional markets in the coming months.
For more information on Nanosphere Health Sciences, Inc. or to schedule an interview, please contact Gabrielle Wesseldyk at [email protected] or 212-255-0945.
On behalf of the Board
Robert Sutton, Chairman and CEO
Office: 720-520-4282
Email: [email protected]
Investor Contact:
Victor Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail: [email protected]
NanoSphere's Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere's licensing program, please visit:https://www.nanospherehealth.com/licensing/
About NanoSphere
NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. Covered by U.S. Patent No. 10,028,919 and U.S. Patent No. 9,925,149, NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve's pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.
Forward Looking Statement Caution
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.
SOURCE NanoSphere Health Sciences, Inc.
Share this article